A detailed history of Securian Asset Management, Inc transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Securian Asset Management, Inc holds 112,132 shares of BMY stock, worth $6.48 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares
112,132
Previous 116,559 3.8%
Holding current value
$6.48 Million
Previous $4.84 Million 19.88%
% of portfolio
0.17%
Previous 0.14%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$39.66 - $51.75 $175,574 - $229,097
-4,427 Reduced 3.8%
112,132 $5.8 Million
Q2 2024

Jul 15, 2024

SELL
$40.25 - $52.99 $132,301 - $174,178
-3,287 Reduced 2.74%
116,559 $4.84 Million
Q1 2024

Apr 26, 2024

SELL
$47.98 - $54.4 $432,827 - $490,742
-9,021 Reduced 7.0%
119,846 $6.5 Million
Q4 2023

Feb 08, 2024

SELL
$48.48 - $57.85 $1.02 Million - $1.22 Million
-21,050 Reduced 14.04%
128,867 $6.61 Million
Q3 2023

Oct 30, 2023

SELL
$57.89 - $64.73 $1.53 Million - $1.71 Million
-26,441 Reduced 14.99%
149,917 $8.7 Million
Q2 2023

Aug 07, 2023

SELL
$63.71 - $70.74 $263,122 - $292,156
-4,130 Reduced 2.29%
176,358 $11.3 Million
Q1 2023

Apr 27, 2023

BUY
$65.71 - $74.53 $49,085 - $55,673
747 Added 0.42%
180,488 $12.5 Million
Q4 2022

Feb 02, 2023

BUY
$68.48 - $81.09 $393,691 - $466,186
5,749 Added 3.3%
179,741 $12.9 Million
Q3 2022

Oct 28, 2022

BUY
$0.13 - $76.84 $177 - $105,117
1,368 Added 0.79%
173,992 $12.4 Million
Q2 2022

Aug 04, 2022

SELL
$72.62 - $79.98 $373,702 - $411,577
-5,146 Reduced 2.89%
172,624 $13.3 Million
Q1 2022

May 03, 2022

SELL
$61.48 - $73.72 $349,759 - $419,393
-5,689 Reduced 3.1%
177,770 $13 Million
Q4 2021

Feb 10, 2022

SELL
$53.63 - $62.52 $305,261 - $355,863
-5,692 Reduced 3.01%
183,459 $11.4 Million
Q3 2021

Nov 08, 2021

SELL
$59.17 - $69.31 $182,184 - $213,405
-3,079 Reduced 1.6%
189,151 $11.2 Million
Q2 2021

Aug 10, 2021

SELL
$61.91 - $67.42 $108,342 - $117,985
-1,750 Reduced 0.9%
192,230 $12.8 Million
Q1 2021

May 10, 2021

SELL
$59.34 - $66.74 $478,695 - $538,391
-8,067 Reduced 3.99%
193,980 $12.2 Million
Q4 2020

Feb 08, 2021

SELL
$57.74 - $65.43 $297,880 - $337,553
-5,159 Reduced 2.49%
202,047 $12.5 Million
Q3 2020

Nov 04, 2020

SELL
$57.43 - $63.64 $205,771 - $228,022
-3,583 Reduced 1.7%
207,206 $12.5 Million
Q2 2020

Aug 06, 2020

SELL
$54.82 - $64.09 $1.17 Million - $1.37 Million
-21,384 Reduced 9.21%
210,789 $12.4 Million
Q1 2020

May 07, 2020

SELL
$46.4 - $67.43 $182,816 - $265,674
-3,940 Reduced 1.67%
232,173 $12.9 Million
Q4 2019

Feb 04, 2020

BUY
$49.21 - $64.19 $3.3 Million - $4.3 Million
66,981 Added 39.6%
236,113 $15.2 Million
Q3 2019

Nov 12, 2019

SELL
$42.77 - $50.71 $59,193 - $70,182
-1,384 Reduced 0.81%
169,132 $8.58 Million
Q2 2019

Aug 05, 2019

BUY
$44.62 - $49.34 $74,113 - $81,953
1,661 Added 0.98%
170,516 $7.73 Million
Q1 2019

Apr 26, 2019

BUY
$45.12 - $53.8 $65,378 - $77,956
1,449 Added 0.87%
168,855 $8.06 Million
Q4 2018

Feb 04, 2019

BUY
$48.76 - $63.23 $22,965 - $29,781
471 Added 0.28%
167,406 $8.7 Million
Q3 2018

Oct 26, 2018

SELL
$55.19 - $62.25 $9,547 - $10,769
-173 Reduced 0.1%
166,935 $10.4 Million
Q2 2018

Aug 09, 2018

BUY
$50.53 - $62.98 $46,083 - $57,437
912 Added 0.55%
167,108 $9.25 Million
Q1 2018

Apr 30, 2018

SELL
$59.92 - $68.98 $44,640 - $51,390
-745 Reduced 0.45%
166,196 $10.5 Million
Q4 2017

Feb 05, 2018

BUY
$59.94 - $65.35 $59,760 - $65,153
997 Added 0.6%
166,941 $10.2 Million
Q3 2017

Nov 03, 2017

SELL
$55.23 - $63.74 $17,563 - $20,269
-318 Reduced 0.19%
165,944 $10.6 Million
Q2 2017

Aug 14, 2017

BUY
N/A
166,262
166,262 $9.26 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Securian Asset Management, Inc Portfolio

Follow Securian Asset Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Securian Asset Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Securian Asset Management, Inc with notifications on news.